Insights
Search Results
Client Highlights
6.17.26
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
News Articles
6.04.26
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
5.05.26
Wilson Sonsini Advises Lattice Semiconductor on $1.65 Billion Acquisition of AMI
On May 4, 2026, Lattice Semiconductor announced it has entered into a definitive agreement with THL Partners to acquire AMI, a leader in platform firmware and infrastructure manageability for cloud and AI. The planned acquisition advances Lattice Semiconductor’s strategy to expand its position in server, AI, and cloud applications spanning hardware, security, manageability, and control. Wilson Sonsini Goodrich & Rosati is advising Lattice Semiconductor on the transaction.
Client Highlights
12.12.25
Wilson Sonsini Advises Denali Therapeutics on $200 Million Public Offering
On December 10, 2025, Denali Therapeutics, a biopharmaceutical company focused on therapies for neurodegenerative and lysosomal storage diseases, announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. Denali Therapeutics expects to receive total gross proceeds of approximately $200 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the transaction.
Client Highlights
11.17.25
Wilson Sonsini Advises onX on Strategic Investment from TCV
On November 3, 2025, onX, a pioneer in digital outdoor navigation and mapping software, announced a strategic investment from TCV, a leading growth equity firm known for supporting enduring consumer technology brands. The partnership brings additional operational expertise and long-term support as onX continues to scale its suite of adventure-specific navigation apps and redefine the outdoor experience. The company's existing investors, including Summit Partners, Madison Valley Partners, and onX founder Eric Siegfried, will remain active board members. Wilson Sonsini Goodrich & Rosati advised onX on the transaction.
News Articles
10.17.25
2026 Lawdragon 500 Leading Dealmakers in America Recognizes Wilson Sonsini Attorneys
On October 17, 2025, Lawdragon published the sixth edition of its Leading Dealmakers in America guide, honoring the lawyers who shake the world with the deals they make happen. The list was compiled through Lawdragon’s time-honed methodology, independent journalistic research, robust and simple submissions from as wide of a group as possible, and vetting from established dealmakers and clients.
Client Highlights
6.18.25
Firm Advises Enliven Therapeutics on $230 Million Public Offering
On June 16, 2025, Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, announced the close of its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and pre-funded warrants to purchase 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven. The gross proceeds from the offering were approximately $230 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Enliven on the offering.
News Articles
6.05.25
2025 Chambers USA Guide Recognizes Wilson Sonsini Practices, Attorneys
The 2025 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 39 geography-specific practice categories and named 86 Wilson Sonsini attorneys among the best in their fields. This year, the firm received three new practice area rankings, including in the Artificial Intelligence category, and four improved practice area rankings.
Client Highlights
4.02.25
Wilson Sonsini Advises Edgewise Therapeutics on $200 Million Underwritten Offering
On April 2, 2025, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025. Wilson Sonsini Goodrich & Rosati represented Edgewise Therapeutics on the transaction.
News Articles
2.13.25
Wilson Sonsini Practices, Attorneys Recognized in 2025 Chambers Global Guide
On February 13, 2025, Chambers and Partners recognized Wilson Sonsini practices and attorneys among the top global lawyers, law firms, and in-house counsel in over 200 jurisdictions in the 2025 edition of its Chambers Global guide. The listings were compiled based on confidential interviews with attorneys and law firm clients to assess firms, practice groups, and individual attorneys on the basis of their technical legal ability, professional conduct, client service, commercial astuteness, diligence, commitment, and other valued qualities.